Testicular Tumor Markers in Diagnosis and Surveillance

Three blood proteins form the backbone of testicular cancer management: alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (beta-hCG), and lactate dehydrogenase (LDH). Together, these tumor markers help doctors diagnose germ cell tumors, estimate how advanced the disease is, gauge treatment response, and watch for recurrence after therapy.¹ No single marker catches every case, though, and the pattern of which markers are elevated varies dramatically depending on the tumor type. Newer molecular tests are closing some of the gaps, but the classic trio remains the standard of care.

What Each Marker Actually Tells You

AFP is a protein normally produced by a developing fetus. In adults, blood levels are usually negligible. When a testicular tumor contains yolk sac elements, embryonal carcinoma, or certain mixed components, those cells can churn out AFP the way fetal tissue does. Elevated AFP in a man with a testicular mass is a strong pointer toward a nonseminomatous germ cell tumor. Research dating back decades confirmed that endodermal sinus tumors (yolk sac tumors) and teratocarcinomas with a yolk sac component reliably raise AFP levels, and that the protein can even be detected inside the tumor tissue itself.² An important clinical rule follows from this: pure seminomas do not produce AFP. If AFP is elevated and the pathology report says “pure seminoma,” the tumor almost certainly has a nonseminomatous component that was missed on the biopsy slides.

Beta-hCG is the hormone behind home pregnancy tests, but certain tumor cells produce it too. In testicular cancer, it comes from syncytiotrophoblastic giant cells, which can appear in choriocarcinoma, embryonal carcinoma, and even some seminomas.³ Because seminomas can contain scattered syncytiotrophoblastic cells, a mildly elevated beta-hCG does not automatically rule out a seminoma the way elevated AFP does. Very high levels, however, strongly suggest choriocarcinoma or a mixed tumor.

LDH is the least specific of the three. It is an enzyme found in many tissues throughout the body, and it can rise with liver disease, muscle injury, or intense exercise. In testicular cancer, LDH levels tend to correlate with overall tumor bulk. Studies have shown that total LDH and its isoenzyme LDH-1 track with tumor volume, and the correlation is especially strong in seminomas.⁴ Because LDH lacks tumor specificity, it is most useful when interpreted alongside AFP and beta-hCG rather than on its own.

Different Tumors, Different Marker Profiles

One of the most practical things to understand about these markers is how starkly they differ between the two main categories of testicular germ cell tumors: seminomas and nonseminomas. A large analysis of germ cell tumor patients found that roughly 28% of pure seminoma patients had elevated beta-hCG, while only about 3% had elevated AFP. In contrast, among nonseminoma patients, about 53% had elevated beta-hCG and around 60% had elevated AFP.⁵ When either beta-hCG or AFP was counted, nearly three-quarters of nonseminoma patients showed at least one elevated marker, compared to roughly 30% of seminoma patients.

These numbers highlight two realities. First, nonseminomas are far more likely to announce themselves through bloodwork. Second, a substantial chunk of testicular cancers, including about 70% of seminomas, will show completely normal marker levels at diagnosis. A normal blood draw does not mean no cancer. Imaging and pathology remain essential regardless of what the markers show.

LDH was somewhat less discriminating between the two groups, elevated in about 29% of seminomas and 39% of nonseminomas in that same analysis. Its main value lies in reflecting disease burden rather than pointing to a specific cell type.

When to Draw Blood and Why Timing Matters

Standard practice calls for measuring tumor markers before the testicle is removed surgically (orchiectomy) and again afterward. Pre-operative levels establish a baseline and can raise suspicion about the tumor type before the pathologist has even looked at the tissue. Post-operative levels, measured after enough time has passed for the markers to clear, reveal whether residual disease remains.

The timing of the post-orchiectomy draw matters because each marker has a known half-life in the bloodstream. AFP clears with a half-life of about five to seven days, while beta-hCG has a shorter half-life of roughly one to three days. If marker levels do not fall at the expected rate after surgery, there is likely tumor left somewhere in the body. Researchers have developed graphical methods to plot the decay curve of each marker after orchiectomy, allowing clinicians to identify patients whose markers are declining too slowly and who therefore harbor residual disease.⁶ The decay pattern and half-life evaluation of these markers have proven to be useful parameters for predicting tumor stage in patients whose imaging may not yet show visible spread.⁷

There is a practical wrinkle here that affects prognosis decisions. International guidelines use post-orchiectomy (and specifically pre-chemotherapy) marker levels to assign patients into risk groups: good, intermediate, or poor prognosis. Some clinicians inadvertently use the pre-orchiectomy marker values instead, which can misclassify risk. One study of 83 patients found that using pre-orchiectomy values instead of the correct pre-chemotherapy values led to upstaging in about 16% of patients and downstaging in one patient.⁸ Being placed in a higher risk category than warranted could mean receiving more aggressive chemotherapy than needed, while being placed lower could mean undertreating the disease. The takeaway: insist that your care team uses the right set of markers, drawn at the right time, for staging decisions.

Markers During Surveillance After Treatment

For men with early-stage testicular cancer who choose active surveillance rather than immediate chemotherapy or radiation, regular blood draws to check tumor markers are part of the follow-up protocol. The idea is to catch a relapse as early as possible. But marker-based surveillance has genuine limits. A systematic review of clinical stage I nonseminomatous germ cell tumors found that markers were elevated in only about 28% to 75% of patients at the time of recurrence. In some series, markers were the sole indication of relapse in as few as 4% to as many as 39% of cases.⁹

That wide range reflects the variability across studies and patient populations, but the bottom line is that markers alone will miss some relapses. This is why surveillance protocols combine blood work with imaging, most commonly CT scans of the abdomen and chest. A rising marker before anything appears on a scan is helpful and triggers further investigation. But the absence of a marker rise does not guarantee everything is clear.

The psychological dimension of surveillance is worth noting. Repeated blood draws and waiting for results can be a source of persistent anxiety. Research on long-term testicular cancer survivors found that roughly one in three reported fear of recurrence even an average of 11 years after diagnosis, and about 17% experienced worsening anxiety related to relapse over time.¹⁰ Understanding that markers are only one piece of the surveillance puzzle, and that the overall prognosis for testicular cancer is excellent, can help put an individual blood draw result in context.

Where the Classic Markers Fall Short

The three standard markers have been in clinical use for decades, and their limitations are well known. The biggest one is sensitivity: in seminomas, fewer than a third of patients have any marker elevation at diagnosis. Even in nonseminomas, about a quarter of patients present with normal AFP, beta-hCG, and LDH. A tumor can be there, growing, and the blood test shows nothing wrong. This means you cannot use a normal marker panel to definitively rule out testicular cancer when there is a suspicious mass on ultrasound.

Specificity is another issue, especially for LDH. Because LDH rises in so many non-cancerous conditions, an isolated mild elevation during surveillance can trigger unnecessary anxiety or additional imaging. Beta-hCG has its own specificity traps: marijuana use has been reported to cause mildly elevated hCG levels, as can hypogonadism (low testosterone states). AFP can be elevated in liver disease. For clinicians, distinguishing a true tumor-related rise from a false alarm requires clinical judgment and often repeat testing over a short interval to see whether the level is trending upward.

These limitations have driven a search for better biomarkers. The field has been pragmatic about the classic trio for a long time, not because the markers are great but because they were the best available and remain incorporated into every international staging and prognosis system.

MicroRNA-371a-3p and the Next Generation of Blood Tests

The most promising new blood marker for testicular germ cell tumors is a tiny fragment of RNA called miR-371a-3p. Unlike AFP, beta-hCG, and LDH, this microRNA is produced by virtually all types of malignant germ cell tumors, whether seminoma or nonseminoma. That universality is what makes it exciting.

A prospective multicenter study found that the miR-371a-3p test (referred to as the “M371 test”) had a sensitivity of about 90% and a specificity of 94% for diagnosing germ cell tumors. The classic markers, by comparison, had sensitivities below 50% for seminoma and only somewhat higher for nonseminomas.¹¹ Other analyses have confirmed high specificity in the 90–99% range, with sensitivity of 84–89% across studies, along with a positive predictive value above 97%.¹² Concentration of the microRNA in the blood also appears to track with tumor burden and respond to treatment, regardless of stage.

From a practical standpoint, the miR-371a-3p test could change two important clinical scenarios. First, it could help clarify ambiguous cases: a man with a testicular mass but completely normal AFP, beta-hCG, and LDH (a common situation in seminoma) could get a blood test that actually reflects the presence of malignant tissue. Second, during surveillance, a more sensitive blood marker could theoretically reduce the number of CT scans needed to catch early relapse, lowering both radiation exposure and cost. Modeling studies have estimated savings of roughly $1,400 per patient when a miR-371a-3p-based surveillance approach replaces part of the current imaging-heavy protocol for stage I nonseminomatous tumors.¹³

The test does have a known blind spot: teratoma. Mature teratomas, which are common in residual masses after chemotherapy, do not express miR-371a-3p. That means a negative microRNA result after chemo does not rule out the presence of teratoma, and surgery to remove residual masses is still guided by imaging and clinical judgment rather than by this blood test alone.

Circulating Tumor DNA

Another technology under investigation is circulating tumor DNA (ctDNA), which involves detecting fragments of tumor-specific genetic material shed into the bloodstream. Early data in testicular cancer has been encouraging. In one study, detectable ctDNA before retroperitoneal lymph node dissection correlated fully with the presence of viable tumor in the removed tissue, while undetectable ctDNA corresponded to benign histology or teratoma on pathology.¹⁴ If validated in larger studies, ctDNA could help decide which patients truly need surgery for post-chemotherapy residual masses and which could safely avoid it. This remains investigational for now, but it represents yet another layer of molecular information beyond what the classic markers offer.

Tissue Markers in Pathology

Everything discussed so far involves serum markers, proteins or nucleic acids measured in a blood sample. But pathologists also use a separate set of markers when examining tumor tissue under the microscope. These immunohistochemical stains help confirm the tumor type and distinguish germ cell tumors from other cancers that can occasionally involve the testicle.

Two commonly used tissue markers are SALL4 and OCT3/4. SALL4 is broadly positive across germ cell tumors, making it a good screening stain. In one study of pediatric testicular tumors, SALL4 was positive in about 83% of cases, with especially strong staining in yolk sac tumors and embryonal carcinoma. OCT3/4 was positive in about 39% of tumors overall but was significantly more common in mixed germ cell tumors and in older adolescent patients (aged 12 to 18) compared to younger children.¹⁵ Other stains used in clinical practice include placental alkaline phosphatase (PLAP) for seminoma, CD30 for embryonal carcinoma, and glypican-3 for yolk sac tumors. These tissue markers do not show up in a blood draw; they require a biopsy or surgical specimen. Their role is to classify what kind of tumor you have rather than to screen or monitor over time.

Why Marker Levels Don’t Always Match What You Expect

It is not unusual for a patient or even a clinician to be surprised by a mismatch between what the markers suggest and what the pathology shows. A few common scenarios cause confusion:

Normal markers with cancer present: As discussed, a large fraction of seminomas and some nonseminomas present with entirely normal AFP, beta-hCG, and LDH. A normal blood panel does not exclude a malignancy.
Elevated AFP in “pure seminoma”: If the biopsy report says pure seminoma but AFP is elevated, the clinical presumption is that nonseminomatous elements are present, even if the pathologist did not find them. The tumor may have been incompletely sampled. Treatment decisions in this situation follow nonseminoma protocols.
Persistent mild beta-hCG elevation without relapse: Small elevations of beta-hCG can occur from cross-reactivity with luteinizing hormone, from hypogonadism (which is common after orchiectomy), or from other non-cancer causes. When a post-treatment beta-hCG is borderline elevated but not rising over serial draws, the cause is often not recurrent cancer.
Rising LDH without other markers: Because LDH is nonspecific, an isolated rise during surveillance requires careful clinical interpretation. A recent intense workout, a viral infection, or even a hemolyzed blood sample can produce a bump. Repeat testing and correlation with imaging usually sort this out.

These mismatches are well-recognized in the field and underscore why tumor markers are interpreted as part of a broader clinical picture rather than as standalone diagnostics.

Pediatric Considerations

Testicular germ cell tumors in children and adolescents share the same basic marker biology as adult tumors, but there are some differences worth noting. AFP is normally elevated in healthy infants and does not reach adult baseline levels until about eight months of age, so interpreting AFP in very young patients requires age-adjusted reference ranges. A level that would be alarming in a teenager could be completely normal in a newborn.

The distribution of tumor subtypes also differs by age. Yolk sac tumors are the most common malignant testicular tumor in prepubertal boys, while adolescents are more likely to develop the mixed germ cell tumors seen in adults. This means AFP is a particularly useful marker in young children, whereas the full panel of AFP, beta-hCG, and LDH becomes more relevant in adolescence. Research into microRNA markers has shown that miRNAs from the miR-371~373 and miR-302/367 clusters are overexpressed in malignant germ cell tumor tissue across all age groups and that serum levels of these microRNAs appear to be sensitive and specific for malignant germ cell tumors in both children and adults.¹⁶ This raises hope that the same next-generation blood tests being studied in adults may eventually benefit younger patients as well.

How Markers Fit into the Bigger Treatment Picture

Tumor markers in testicular cancer are woven into nearly every decision point along the treatment pathway. Before surgery, they help refine suspicion about tumor type. After surgery, their rate of decline determines whether the operation was curative or whether further treatment is needed. Before starting chemotherapy, their absolute levels help assign a prognosis category that dictates how many cycles of chemotherapy to give. During chemotherapy, falling markers suggest the treatment is working; plateauing or rising markers signal possible resistance. After chemotherapy, they factor into whether residual masses need to be surgically removed.

No other solid cancer relies so heavily on a small set of blood tests at every stage of management. This is partly because testicular cancer is so treatable that getting the treatment intensity right matters enormously. Under-treating a poor-prognosis tumor can cost someone their life, while over-treating a good-prognosis tumor exposes a young man to unnecessary toxicity from extra chemotherapy cycles. Markers, for all their imperfections, remain the main tool clinicians use to calibrate that balance. As newer tests like miR-371a-3p and ctDNA mature from research tools into validated clinical assays, the toolkit is likely to become sharper, though the fundamental role of blood-based biomarkers in this disease is not going to change anytime soon.